Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | EYA2 | O00167 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438113 | 1.00 | TDP1 (0.58) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL4621864 | 1.00 | TDP1 (0.58) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL19458 | 0.92 | TDP1 (0.42) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL437106 | 0.92 | TDP1 (0.48) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL6859731 | 0.91 | TDP1 (0.47) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL7129262 | 0.91 | TDP1 (0.47) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL419703 | 0.90 | TDP1 (0.42) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL18145576 | 0.90 | TDP1 (0.42) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL6227790 | 0.89 | TDP1 (0.45) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL19952793 | 0.89 | TDP1 (0.45) | TDP1BLMPMP22KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135047-A1 | IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | claimed |
| CN-116761810-A | Imaging and targeting of programmed death ligand-1 (PD-L1) expression | 约翰霍普金斯大学 | 2023-09-15 | — | — | CN | claimed |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSTY | 2023-08-31 | — | — | US | claimed |
| EP-4192524-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | The Johns Hopkins University (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2023014999-A1 | ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | WO | claimed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| US-9266846-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-12583945-B2 | Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250135047-A1 | IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| US-20250127941-A1 | DETECTION AND LOCALIZATION OF INTERNAL BLEEDING | CUMBERLAND EMERGING TECHNOLOGIES, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4463189-A1 | DETECTION AND LOCALIZATION OF INTERNAL BLEEDING | Vanderbilt University (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024220548-A2 | MOLECULAR-MRI USING CCR2-TARGETED MICELLES FOR DETECTION OF LYMPH NODE METASTASES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240092944-A1 | SYNTHESIS OF UNIFORMLY DEFINED MOLECULAR WEIGHT MANNOSYLATED DEXTRANS AND DERIVATIVES THEREOF | SCOTT, JOHN KIM, JR. | 2024-03-21 | — | — | US | disclosed |
| EP-0810990-A1 | SUBSTITUTED DTPA MONOAMIDES OF CENTRAL CARBOXYLIC ACIDS AND METAL COMPLEXES THEREOF, PHARMACEUTICALS CONTAINING THESE COMPLEXES, DIAGNOSTIC AND THERAPEUTIC USES THEREOF AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-10 | — | — | EP | disclosed |
| US-5679852-A | Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| US-5676926-A | Process for the production of DTPA-tetraesters of terminal carboxylic acids | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-14 | — | — | US | disclosed |
| US-5676923-A | SOLUBLE, STABLE, ORGAN-SPECIFIC NUCLEAR MAGNETIC RESONANCE CONTRAST AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-14 | — | — | US | disclosed |
| WO-1997002051-A2 | CASCADE POLYMER COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-01-23 | — | — | WO | disclosed |
| WO-1996026182-A1 | SUBSTITUTED DTPA MONOAMIDES OF CENTRAL CARBOXYLIC ACIDS AND METAL COMPLEXES THEREOF, PHARMACEUTICALS CONTAINING THESE COMPLEXES, DIAGNOSTIC AND THERAPEUTIC USES THEREOF AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-08-29 | — | — | WO | disclosed |
| US-5514810-A | Process for the production of DTPA-tetraesters of terminal carboxylic acids | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | CD274, PDCD1LG2, PDCD1 | TDP1 1516/4885BLM 2087/4885PMP22 1263/4885 |
| US-20250135047-A1 | IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | PDCD1LG2, CD274, PDCD1 | TDP1 2019/4885BLM 2160/4885PMP22 442/4885 |
| US-20240092944-A1 | SYNTHESIS OF UNIFORMLY DEFINED MOLECULAR WEIGHT MANNOSYLATED DEXTRANS AND DERIVATIVES THEREOF | SI, CD44, ALG1 | TDP1 4020/4885BLM 3441/4885PMP22 1266/4885 |
| US-12583945-B2 | Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof | CD209, FUT6, CD47 | TDP1 3697/4885BLM 3505/4885PMP22 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.